LGVN (Longeveron) Year-over-year earnings per share growth for the last twelve months

Corporate company logo of Longeveron (LGVN)

The current quarterly EPS rate reflects the dynamics of a regenerative innovator associated with longevity and scientific trust, with the current value equal to 51.80. Longeveron Inc. (LGVN) bases its business foundation on the efficacy of Lomecel-B in treating Alzheimer's disease. The company's strategy relies on niche research, allowing it to avoid pricing conflicts while focusing on attracting investment capital.

longeveron.com (LGVN) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Longeveron Inc.

- market value and analyst target forecast:
- business market valuation indicators:
Fundamental valuation:longeveron.com - LGVN
Flagship merchandise of longeveron.com

Longeveron Inc. utilizes efficient cryogenic logistics to minimize the loss of high-cost cell therapies, directly supporting the business's operating margins and financial stability. By analyzing the trend of quarterly earnings per share growth, an investor can track the dynamics of net income per share, where sharp peaks signal that the asset is overbought, while prolonged declines define the risks of further valuation depreciation.